title: A longitudinal analysis of antimicrobial susceptibility in clinical institutions in Germany as part of the Tigecycline Evaluation and Surveillance Trial (2004-2007).
abstract: BACKGROUND
  The Tigecycline Evaluation and Surveillance Trial (T.E.S.T.) global surveillance program has been designed to assess the in vitro activity of the broad-spectrum antimicrobial agent tigecycline plus several comparative agents.
  
  
  METHODS
  In vitro activities of bacterial isolates obtained from 13 centers in Germany between 2004 and 2007 were evaluated longitudinally and pooled, using the interpretive criteria of the European Committee on Antimicrobial Susceptibility Testing (EUCAST).
  
  
  RESULTS
  Tigecycline demonstrated good activity against both Gram-positive and -negative pathogens monitored in this study [minimum inhibitory concentration (MIC) required to inhibit the growth of 90% of organisms (MIC(90)) 0.06-2 microg/ml] with the exception of Pseudomonas aeruginosa, which had elevated MICs for most antimicrobial agents. Imipenem and meropenem also showed good activity (MIC(90) <or=0.06-4 microg/ml) against most Gram-negative pathogens but were less active against Gram-positive organisms (MIC(90) <or=0.12 to >or=32 microg/ml).
  
  
  CONCLUSIONS
  Tigecycline was highly active against most pathogens monitored in the T.E.S.T. study. A low tigecycline MIC(90) was reported against Acinetobacter baumannii and drug-resistant Enterococcus faecium,Staphylococcus aureus and Escherichia coli. The carbapenems showed the lowest MIC(90) values against extended-spectrum beta-lactamase-positive E. coli. E. coli susceptibility to most antimicrobial agents decreased over the course of this study.
authors.affiliation: Institute for Medical Microbiology, Immunology and Hygiene, University of Cologne, Cologne, Germany. harald.seifert@uni-koeln.de
authors.forename: Harald
authors.initials: H
authors.lastname: Seifert
authors.forename: Michael J
authors.initials: MJ
authors.lastname: Dowzicky
mesh_terms: D000900:Anti-Bacterial Agents / Q000494:pharmacology*; D024881:Drug Resistance, Bacterial; D005858:Germany; D006090:Gram-Negative Bacteria / Q000187:drug effects / Q000302:isolation & purification; D006094:Gram-Positive Bacteria / Q000187:drug effects / Q000302:isolation & purification; D006268:Health Facilities; D006801:Humans; D008137:Longitudinal Studies; D008826:Microbial Sensitivity Tests / Q000379:methods; D008911:Minocycline / Q000031:analogs & derivatives* / Q000494:pharmacology; D015337:Multicenter Studies as Topic; D011358:Product Surveillance, Postmarketing; D000078304:Tigecycline
chemical_list: D000900:Anti-Bacterial Agents; D000078304:Tigecycline; D008911:Minocycline